Company intelligence / Profile preview

Quellis Biosciences

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Quellis Biosciences was focused on developing antibody-based therapies for rare, life-threatening diseases, most notably hereditary angioedema. Its lead program, QLS-215, is a humanized monoclonal antibody targeting plasma kallikrein with demonstrated potent inhibition and extended plasma half-life in preclinical models. The company was acquired by Catabasis Pharmaceuticals, with plans to advance QLS-215 into clinical trials.

Therapeutic areas: Immunology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Xontogeny (life sciences accelerator)

Beyond the preview

Go deeper on Quellis Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quellis Biosciences.

Explore the full profile